The ratings of 10 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a D to a F rating, Novartis AG Sponsored ADR (NVS) takes a hit this week. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Astrazeneca PLC Sponsored ADR (AZN) declines this week from a C to a D. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For more information, get Portfolio Grader’s complete analysis of AZN stock.

This week, Catalent Inc (CTLT) drops from a C to a D rating. The company also gets F’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CTLT stock.

Flex Pharma, Inc. (FLKS) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

This is a rough week for Flamel Technologies SA Sponsored ADR (FLML). The company’s rating falls to F from the previous week’s D. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of FLML stock.

KemPharm, Inc.’s (KMPH) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

Marinus Pharmaceuticals Inc (MRNS) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Aradigm Corporation (ARDM) slips from a D to a F this week. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDM stock.

Acura Pharmaceuticals, Inc. (ACUR) gets weaker ratings this week as last week’s D drops to a F. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in sales growth, earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

DURECT Corporation (DRRX) earns a F this week, moving down from last week’s grade of D. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.